

## CURRICULUM VITAE

### WILLIAM N. KELLY, PHARM.D, FISPE

William N. Kelly Consulting, Inc.  
2147 Warwick Drive  
Oldsmar, FL 34667

(770) 855-5571 (B)  
(727) 786-3424 (fax)

wnkelly@earthlink.net  
wkelly@visanteinc.com  
www.williamnkelly.com

June 25, 2008

#### EDUCATION:

PharmD: College of Pharmacy, University of Michigan, Ann Arbor, Michigan

M.S. Candidate: Pharmacoepidemiology, School of Epidemiology and Biostatistics,  
McGill University, Montreal, Canada

Course work completed in pharmacoepidemiology and biostatistics at Emory University  
School of Public Health, Atlanta, Georgia

B.S. Pharmacy: School of Pharmacy, Ferris State University, Big Rapids, Michigan

#### TRAINING:

Fellowship: Healthcare Executive Management, The Leonard Davis Institute of Health Economics,  
Wharton School of Finance, University of Pennsylvania, Philadelphia, Pennsylvania

Residency: University Hospital, Department of Pharmacy, University of Michigan Medical Center, Ann  
Arbor, Michigan

Internship: White and White Pharmacy, Inc., Grand Rapids, Michigan

#### PROFESSIONAL EXPERIENCE:

2008 Part-time pharmacist, Westchase Compounding Pharmacy, Tampa, FL

2007 to present Vice President for Scientific Affairs, Visante, Inc., Eden Prairie, MN

2005 to present President, William N. Kelly Consulting, Inc., Oldsmar, Florida

2005 to present Adjunct Professor of Pharmacy, School of Pharmacy, Mercer University, Atlanta, Georgia

1999 - 2004 Full Professor, Department of Pharmacy Administration, School of Pharmacy, Mercer  
University, Atlanta, Georgia

1998 - 2004 Visiting Researcher, Centers for Disease Control and Prevention (CDC)  
National Immunization Program, Epidemiology and Surveillance Division, Immunization  
Safety Branch, Atlanta, GA

1998 Tenured Professor, Mercer University, Atlanta and Macon, Georgia

1992 - 1999 Full Professor and Chairman, Department of Pharmacy Practice, School of Pharmacy, Mercer  
University, Atlanta, Georgia

1991 - 1992 Acting Senior Vice President, Hamot Medical Center, Erie, Pennsylvania (550 beds)

1990 - 1991 Assistant Vice President, Hamot Medical Center, Erie, Pennsylvania

1980 - 1992 Director, Pharmacy and Drug Information Service, Hamot Medical Center, Erie, Pennsylvania

1987 - 1992 President, Bayside Pharmacy Services, Inc., a subsidiary of Hamot Health Systems, Inc., Erie,  
Pennsylvania

1989 - 1990 Chairman of the Board and President, Great Lakes Home Healthcare Services, Inc., a subsidiary of Hamot Health Systems, Inc., Erie, Pennsylvania

1977 - 1980 Associate Director, Pharmacy and Drug Information Service, Hamot Medical Center, Erie, Pennsylvania

1972 - 1979 Director, Drug and Poison Information Services, Hamot Medical Center, Erie, Pennsylvania

1972 - 1976 Assistant Director, Pharmacy and Drug Information Service, Hamot Medical Center, Erie, Pennsylvania

1968 - 1970 Staff Pharmacist, White and White Pharmacy, Inc., Grand Rapids, Michigan

**WORK APPOINTMENTS:**

Mercer University

2001 - 2002 Member, Executive Committee, Faculty House of Delegates

1997 - 2001 Member, University Long Range Planning Council

1994 - 1996 Chairman, Employee Benefits Committee, Mercer University

1993 - 1996 Member, Employee Benefits Committee, Mercer University

Mercer School of Pharmacy

2003 - 2004 AACP Faculty Representative

2001 Member, Steering Committee for ACPE Self-Study

2001 - 2003 Member, Faculty Council

1999 - 2001 Member, Promotion and Tenure Committee

1998 - 2004 Advisor, Kappa Psi

1996-1999 Coordinator, Strategic Planning

1997-1999 Member, Educational Resources Committee

1997 - 2002 Member and Innovator, The Center for Health Outcomes Research

1994 - 1996 Director, Mercer University Pharmacy Residency Program

1994 - 1996 Chairman, Task Force to Develop a Joint External Pharm.D. Program

1993 - 1999 Advisor, Student Chapter of CPFI

1992 -1993 Member, Curriculum Committee Task Force for Semester Conversion

1992 - 1999 Member, Academic Executive Committee

1992 – 2004 Admissions Interview Team

1992 - 2004 Student Academic Advisor

Hamot Medical Center

1990 - 1992 Member, Quality Improvement Team

1990 - 1992 Member, Medical Ethics Committee

1987 - 1992 Member, Board of Directors, Great Lakes Home Healthcare Services, Inc.

1986 - 1991 Secretary, Patient Care Committee of the Medical Staff

1981 - 1992 Director, Clinical Pharmacy Residency Program (one of the first three to be accredited by the American Society of Hospital Pharmacists in February, 1981).

1980 - 1992 Secretary, Pharmacy and Therapeutics Committee

1980 - 1987 Secretary, Investigational Review Board, Hamot Health Systems, Inc.

**ACADEMIC APPOINTMENTS:**

2005 to present Adjunct Faculty, Mercer University, School of Pharmacy, Atlanta, Georgia

1998 - 2004 Tenured Professor, Mercer University, School of Pharmacy, Atlanta, Georgia

1993 - 2004 Graduate Faculty, Mercer University, School of Pharmacy, Atlanta, Georgia

1992 - 2004 Professor, Mercer University, School of Pharmacy, Atlanta, Georgia

1990 - 1992 Adjunct Associate Clinical Professor, University of Pittsburgh, School of Pharmacy, Pittsburgh, Pennsylvania

1988 - 1992 Adjunct Associate Clinical Professor, University of Kentucky, College of Pharmacy, Lexington, Kentucky

1978 - 1987 Adjunct Assistant Clinical Professor, University of Kentucky, College of Pharmacy, Lexington, Kentucky

1976 - 1978 Adjunct Instructor of Pharmacy, Duquesne University, School of Pharmacy, Pittsburgh, Pennsylvania

1975 - 1977 Adjunct Clinical Instructor, University of Kentucky, College of Pharmacy, Lexington, Kentucky

1974 - 1980 Instructor, Certified Nurse Anesthetist Program, Conducted by Hamot Medical Center and Edinboro State College

1972 Teaching Assistant, University of Michigan, College of Pharmacy, Ann Arbor, Michigan

**TEACHING:**

Didactic

Mercer School of Pharmacy

- Drug Misadventures - Initiated, coordinated and taught
- Biostatistics - Helped teach
- Introduction to Pharmacy - Coordinated, taught and wrote text
- Law & Ethics - Coordinated and taught
- Management - Helped teach

Experiential

Precepted students in Research (P-4), 1999 - 2004.

Precepted students in Drug Information rotations (P-4) at Grady Hospital (1992-94) and at Mercer (1975-1999).

Residency

Hamot Medical Center - Initiated the Clinical Pharmacy Residency Program and helped train 30 residents (1974-92).

Mercer School of Pharmacy – Residency Director (1994-96). During this time, 21 residents received residency certificates.

### Fellowship

Mercer School of Pharmacy - Co-developed and helped teach the first fellowship in Pharmacy Automation in the U.S. (1994-96).

### **EDITORIAL ACTIVITIES:**

2007	Peer Reviewer, <i>Lancet</i>
2007	Peer Reviewer, <i>Drug Safety</i>
2003 to 2006	Member, Advisory Board, ASHP Education and Research Foundation
2002 to present	Member, Editorial Board, <i>Clin-Alert</i>
2001 to present	Member, Editorial Board, <i>Journal of Pharmacy Practice</i>
1996 to present	Co-Editor, Adverse Drug Event Column, <i>American Journal of Therapeutics</i> .
1995 - 1998	Editor, <i>Southern Journal of Health-System Pharmacy</i>
1995 - 2000	Editor, Adverse Drug Event Column, <i>Journal of Pharmacy Practice</i>
1995 - 2000	Member, Editorial Board, <i>Journal of Pharmacy Practice</i>
1982 to present	Referee, <i>American Journal of Health-System Pharmacy</i>
1979 to 1992	Referee, <i>Hospital Pharmacy</i>
1979 - 1980	Book Reviewer, <i>Annals of Internal Medicine</i>
1978 - 1982	Referee, <i>Drug Intelligence and Clinical Pharmacy</i>

### **CONSULTANSHIPS:**

2006	Consultant, Computer Technology Associates, Inc. – Rockville, MD
2005	Consultant, XLHealth, Baltimore, MD
2005 to date	Consultant, VigiLanz, Minneapolis, MN
2005 to date	Senior Consultant, Gorman Health Group, Washington, DC
2004 to 2005	Consultant, Envision Change, Inc., Richmond, VA.
2001 to date	Consultant, Visante, Inc., Eden Prairie, MN
1995 to date	Consulting and testifying expert in legal cases involving drug misadventures
1987 - 1988	Consultant, McGraw-Hill Publishing Company, Biomedical Information Division, New York, New York
1985 - 1988	Clinical Investigator and Consultant, Infusion Division, Becton-Dickinson Inc., Fairfield, New Jersey
1978 - 2000	Member, Hospital Pharmacy Speaker's Bureau, Eli Lilly and Company
1975 - 1978	Member, Speaker's Bureau, Hospital Division, Abbott Laboratories
1974 - 1981	Consulting Editor for <i>Drug Topics</i>

**PROFESSIONAL ACTIVITIES:**

Chair	Task Force on Assessing Causality and Publishing ADE Reports. International Society of Pharmacoepidemiology (2004-2007)
Member	Subcommittee on the Journal of Pharmacoepidemiology and Drug Safety (Committee on Publication), International Society for Pharmacoepidemiology (2003-2005)
Member	Public Relations Committee, International Society for Pharmacoepidemiology (2003-2005)
Member	Research Advisory Board, ASHP Research and Education Foundation (2003-2005)
Member	Selection Panel, ASHP Research and Education Foundation Research Grants Program. Grants for Medication Safety Research (2001 and 2002)
Chairman	Safe Medication Use Expert Committee, the United States Pharmacopeia (2000-2005)
Member	National Coordinating Council for Medication Error and Prevention (2000-2005)
Member	Vaccines, Virology, Immunology Expert Committee, The United States Pharmacopeia (2000-2002)
Member	Editorial Advisory Board, "Briefings on Adverse & Sentinel Events," Opus Communications, Inc., Marblehead, MA (1999 - date)
Reviewer	ASHP Foundation Research Grants Program, 1998
Chairman	Editorial Board, Georgia Society of Health-System Pharmacists (1994 - 1998)
Member	Annual Meeting Program Committee, International Society for Pharmacoepidemiology (1996 and 1997)
Member	Pharmacy Technician Task Force, Georgia State Board of Pharmacy (1995)
Member	Board of Directors, American Society of Hospital Pharmacists (1991-1995)
Co-Chairman	Pharmaceutical Care Task Force, Georgia Society of Hospital Pharmacists (1992-1994)
Member	Advisory Committee, Executive Management Program for Directors of Hospital Pharmacy, Leonard Davis Institute of Health, Wharton School, University of Pennsylvania (1990)
Liaison	Pennsylvania Medical Society from the Pennsylvania Society of Hospital Pharmacists (1989-1991)
Member	Long Range Planning Committee, Pennsylvania Society of Hospital Pharmacists (1988-1992)
Member	Council on Administrative Affairs, American Society of Hospital Pharmacists (1987 & 1988)
Vice Chairman	Commission on Goals, American Society of Hospital Pharmacists (1986)
Member	Commission on Goals, American Society of Hospital Pharmacists (1984-1985)
Member	Advisory Working Group (Education) to the Administrative SIG, American Society of Hospital Pharmacists (1984)
Member	Committee on Nominations, American Society of Hospital Pharmacists (1983-1987)
Member	House of Delegates, American Society of Hospital Pharmacists (1982-1987)
Secretary	Trustee Group for Pennsylvania Pharmacists (1982)

Secretary	Council for Pharmacy in Pennsylvania (1980-1981)
President	Pennsylvania Society of Hospital Pharmacists (1979-1980)
President-Elect	Pennsylvania Society of Hospital Pharmacists (1978)
Board Member	Pennsylvania Society of Hospital Pharmacists (1976-1981)
Member	Council on Legal and Public Affairs, American Society of Hospital Pharmacists (1976-1980)
Editor	Pennsylvania Society of Hospital Pharmacists Newsletter (1976-1978)
President	Northwestern Pennsylvania Society of Hospital Pharmacists (1976)
President-Elect	Northwestern Pennsylvania Society of Hospital Pharmacists (1975)
Secretary and Co-Founder	Northwestern Pennsylvania Society of Hospital Pharmacists (1973-1974)

**OTHER PROFESSIONAL APPOINTMENTS:**

Member	Advisory Board, ABC Home Healthcare, Atlanta, Georgia (1992-1994)
Chairman	Pharmacy and Therapeutics Committee, Shriners Hospital for Crippled Children, Erie, Pennsylvania (1981-1991)
Member	Scientific Medical Staff, Shriners Hospital for Crippled Children, Erie, Pennsylvania (1981-1991)
Member	Associate Medical Staff, Lake Erie Institute of Rehabilitation, Erie, Pennsylvania (1985-1986)
Member	Executive Committee, Lake Area Health Education Center, (LAHEC) N.W. Pennsylvania Region (1978-1980)
Member	Oversight Committee for Drug Utilization Review, Pennsylvania Medical Care Foundation (Pennsylvania PSRO) (1976-1980)
Chairman	Drug Utilization Review Committee PSRO Region 1, Pennsylvania Medical Care Foundation - Pennsylvania Department of Welfare (1975-1978)

**PROFESSIONAL MEMBERSHIPS:**

American Society of Health-System Pharmacists (ASHP)

American Society for Pharmacy Law (ASPL)

International Society for Pharmacoepidemiology (ISPE)

**OTHER ACTIVITIES AND AWARDS:**

Fellow, International Society for Pharmacoepidemiology (ISPE), 2004

Member, Kappa Psi, 1997-present

Pharmacist of the Year, Pennsylvania Society of Hospital Pharmacists, 1991

Graduate, the Philip Crosby Quality Management College, Deerfield, Illinois, 1990

International travel to the Soviet Union and the Republic of China to study health care systems and the practice of pharmacy, and to lecture on "Clinical and Hospital Pharmacy Practice in the United States", July, 1983

Distinguished Alumni Award, Central High School, Bay City, Michigan (June) 1980

Outstanding Young Man of America, 1976 (U.S. Jaycees)

Dale Carnegie Graduate, 1970

**PUBLICATIONS:**

Peer Reviewed Journal Articles

Belknap SM, Georgopoulos CH, West DP, Yarnold PR, and Kelly WN. Quality of adverse drug event reporting in cancer drug clinical trials. *Lancet*. Submitted 2008.

Kelly WN, HogenEsch H, Jones JF, and Chen RT. Murine antibody responses to human vaccines. *Clin Vaccine and Immunology*. Submitted 2008.

Kelly WN, Arellano FM, Barnes J, Bergman U, Edwards IR, Fernandez SB, Goldsmith DI, Huang KA, Jones JK, McLeay R, Moore N, Stather RH, Trenque T, Troutman WG, van Puijenbroek E, Williams F, and Wise RP. Guidelines for submitting adverse event reports for publication. *Drug Safety*. 2007;30(5):367-373.

Kelly WN, Arellano FM, Barnes J, Bergman U, Edwards IR, Fernandez SB, Goldsmith DI, Huang KA, Jones JK, McLeay R, Moore N, Stather RH, Trenque T, Troutman WG, van Puijenbroek E, Williams F, and Wise RP. Guidelines for submitting adverse event reports for publication. *Pharmacoepidemiology and Drug Safety*. 2007;16:581-587.

Kelly WN. Compelling features of a safe medication system. *Am J Health-Syst Pharm*. 2006;63(15):1461-1468.

Al-Tajir G and Kelly, WN The epidemiology, comparative methods of detection, and preventability of adverse drug events. *Annals of Pharmacotherapy*. 2005;39:1169-1174.

Kelly WN. Medication errors: Lessons learned and actions needed. *Professional Safety*. 2004;49(7):35-41.

Kelly WN. The quality of published adverse drug event reports. *Annals of Pharmacotherapy*. 2003;37(12):1774-1778.

Kelly WN. Course portfolio: My first experience with problem-based learning. The Center for Problem-Based Learning. Samford University.  
<http://www.samford.edu/pbl/pblpr/williamkelly/>. December 18, 2002.

Anderson, RJ, Alabi, RA, Kelly, WN, and Diseker, DR Risk of myocardial infarction with combination antihypertensive regimens including dihydropyridine calcium channel blocker in hypertensive diabetics.  
<http://www.amcp.org/jmcp/vol9/num1/index.pdf>. *Am J Managed Care Pharmacy*. 2003;9(1):29-35.

Kelly WN. First do no harm: Reducing medication errors in long-term care facilities. *Ann Long-Term Care*. 2002;10(4):49-56.

Kelly WN. Clin-Alert: Its value to education, research, and practice. *Medscape Pharmacists*.  
<http://www.medscape.com>. March 15, 2002.

Kelly WN. Vaccine safety and the pharmacist. *Medscape Pharmacists*.  
<http://www.medscape.com/viewarticle/420688>. February 12, 2002.

Kelly WN. Potential risks and prevention, part 4: Reports of significant adverse drug events. *Am J Health-Sys Pharm*. 2001;58:1406-1412.

Marcellino K and Kelly WN. Potential risk factors and prevention, part 3: Drug-induced threats to life. *Am J Health-Sys Pharm*. 2001;58:1399-1405.

Kelly WN. Potential risks and prevention, part 2: Drug-induced permanent disabilities. *Am J Health-Sys Pharm*. 2001;58:1325-1329.

Kelly WN. Potential risks and prevention, part 1: Fatal adverse drug events. *Am J Health-Sys Pharm*. 2001;58:1317-1324.

Kelly WN. Can the frequency and risks of fatal adverse events be determined? *Pharmacotherapy*. 2001;21:521-527.

O'Donnell, J, Mertl, SL, and Kelly, WN. Propylene glycol toxicity in a pediatric patient: The dangers of diluents. *J Pharm Practice* 2000;13:214-225.

Argo AL, Cox KK, and Kelly WN. The ten most common lethal medication errors in hospital patients. *Hosp Pharm.* 2000;35:470-474.

Kelly WN, Francisco GE, Brooks PJ, and Marquess JG. Development of a non-traditional Pharm.D. program offered jointly between a private and public university. *Am J Pharm Ed.* 2000;64:59-61.

O'Donnell JO, Mertl SL, and Kelly WN. Calcium-channel blocker withdrawal in a pregnant woman. *Am J Therapeutics.* 1999;6:61-66.

Kelly WN. Documentation and reimbursement for pharmaceutical care. *Southern J Health-Sys Pharm.* 1997;2:6-14.

Williams SJ, Kelly WN, Grapes ZT, Haymond JD. Current use of automation in the United States. *Hosp Pharm* 1996;31:1093-1101.

Miller SW and Kelly WN. Certificate programs in pharmacy practice: Descriptions and availability. *Consult Pharmacist.* 1996;11(4):381-386.

Kelly WN. Pharmacy contributions to adverse medication events. Proceedings of the ASHP/AMA/ANA Conference on Understanding and Preventing Drug Misadventures. *Am J Hosp Pharm.* 1995;52:385-390.

Kelly WN, Chrymko M, and Bender, F. Interest and resources for nontraditional Pharm.D. Programs in Pennsylvania. *Am J Pharm Ed.* 1994;58:171-176.

Chrymko M, Meyer JD, and Kelly WN. Target drug monitoring: A cost-effective service provided by staff Pharmacists. *Hosp Pharm.* 1994;29:347-352.

Kelly WN and Rucker TD. Considerations in deciding which drugs should be in a formulary. *Pharm Prac.* 1994;7:51-57.

Kelly WN. Use of an antiemetic drug by a pregnant woman. *Am Hosp Pharm.* 1993;50(Jan):109-112.

Kelly WN. Pharmacist's responsibility for providing drug information to be used for questionable purposes. *Am J Hosp Pharm.* 1992;49:1727-28.

Kelly WN, Small T, Krowinski W, and Drane J. Ethical issues presented to drug information centers: A national survey. *Am J Hosp Pharm.* 1990;47:2245-2250.

Martucci, JD and Kelly WN. Monitoring the financial performance of the pharmacy department. *Top Hosp Pharm Management.* 1989;9:49-58.

Chrymko, M. M., and Kelly, W. N. Clinical career ladders: Hamot Medical Center. *Am J Hosp Pharm.* 1989;46: 2268-2271.

Kelly WN. The pharmacy annual report to administration: Hamot Medical Center. *Hosp Pharm.* 1988;23:407-408.

Kelly WN. Hospital diversification: Case studies of pharmacy involvement. Hamot Health Systems. *Am J Hosp Pharm.* 1987;44:2041-2043.

Fiorenzo VJ and Kelly WN. A financial evaluation of the BD 360 infuser system. *Hosp Pharm.* 1987;22:563-566 .

Kelly W N. Strategic planning for clinical services: Hamot Medical Center. *Am J Hosp Pharm.* 1986;43:2159-2163.

Kelly WN, Meyer JD, and Flatley CJ. Cost analysis of a satellite pharmacy. *Am J Hosp Pharm.* 1986;43:1927-1930.

Meyer JD, Brundige ML, and Kelly WN. Development of a pharmacy-based home healthcare program. *Am J Hosp Pharm.* 1986;43:406-409.

Chase K, Meyer JD, and Kelly WN. Total formulary review - the easy way. *Hosp Pharm.* 1984;19:159-162.

Kelly WN. Total cost of antibiotic therapy. *Infections in Surgery.* 1984;(Jan):22-23.

- Kelly WN. Implementing and maintaining a viable formulary. *Hosp Form*. 1983;18:976-987.
- Kelly WN and Christensen L. Selective patient criteria for the use of electronic infusion devices. *Am J IV Ther Clin Nutr*. 1983;10:18-29.
- Kelly WN, Gibson G, and Miller DE. Charging and receiving reimbursement for pharmacokinetic monitoring. *Am J Hosp Pharm*. 1982;39:1662-1665.
- Kelly WN and Seaver DJ. Strategic planning for clinical services. *Am J Hosp Pharm*. 1981;38:1786-1788.
- Bollish, Stephen J., Kelly, William N., Miller, Douglas E., and Timmons, Robert G. Establishing an aminoglycoside pharmacokinetic monitoring service in a community hospital. *Am J Hosp Pharm*. 1981;38:73-76.
- Berg MJ, Lantz RK, Francis P, Kelly WN, Kostenbauder HB, Hughes M, and Latta R. Erythrocyte lithium and the erythrocyte: Plasma ratio as indicators of mood changes: Preliminary report. *Drug Intell Clin Pharm*. 1980;14:836-842.
- Kelly WN. Why antibiotics sometimes fail. *Diagnostic Medicine*. 1979;2:26-45.
- Kelly WN. Antibiotics: Superdrugs against bacteria. *Diagnostic Medicine*. 1979;2:35-42.
- Halbert MR, Kelly WN, and Miller DE. Drug information centers: Lack of generic equivalence. *Drug Intell Clin Pharm*. 1997;11:728-735.
- Kelly WN and Miller DE. Drug utilization review program with teeth in it. *Hosp Form Mgt*. 1977;12:194-195.
- Kelly WN, Miller DE, and Mahaffy PR. Initiating and justifying an IV team concept. *Am J IV Therapy* (Nov) 1975.
- Kelly WN, White JA, and Miller DE. Drug usage review in a community hospital. *Am J Hosp Pharm*. 1975;32: 1014-1017.
- DiPirro MN, Kelly WN, and Miller DE. Developing a clinically-oriented drug Information service in a Community hospital. *Hosp Pharm*. 1975;57:34-35.
- Kelly WN and Miller DE. Erie County RX forge alert system. *Penn Pharm*. 1974;57: 34-36.
- Kelly WN. Liquid antacids - A review. *Hosp Form Mgt*. 1974;9:36-27.
- Kelly WN and Ice RA. Pharmaceutical quality of technetium-99m sulfur colloid. *Am J Hosp Pharm*. 1973;30: 817-820.
- Books
- Kelly WN. Pharmacy: What It Is and How It Works, 2<sup>nd</sup> edition. CRC Press, Boca Raton, Florida. In press, 2006.
- Kelly WN. Prescribed Medications and the Public Health: A Foundation for Reducing Risk. Haworth Press, Inc., Binghamton, NY. July 30, 2006.
- Kelly WN. Pharmacy: What It Is and How It Works. 1<sup>st</sup> edition. CRC Publishing Company, Boca Raton, Florida. March 27, 2002.
- Chapters in Books and Book Introductions
- Kelly WN. The Role of Pharmacoepidemiology in Drug Injury and Expert Testimony. Chapter 11 in Drug Injury: Liability, Analysis and Prevention. Second Edition. Edited by James T. O'Donnell. Lawyers and Judges Publishing Company. Tucson, AZ. 2005.
- Kelly WN. Drug Use Control: The Foundation of Pharmaceutical Care. A Chapter in Pharmacy Practice for Technicians, 3<sup>rd</sup> edition. Delmer Publishers, Inc. Clifton Park, New York. 2004.
- Kelly WN. Drug Use Control: The Foundation of Pharmaceutical Care. A chapter in Pharmacy Practice for Technicians, 2nd edition. Delmer Publishers, Inc., Albany, New York. 1999.
- Kelly WN. Introduction in The JCAHO and Medication Use: A Monograph on Compliance and Good Practice, Maureen M. Wrinn, Editor. Opus Communication, Marblehead, Mass. 1995.

Kelly WN. Drug Use Control: The Foundation of Pharmaceutical Care. Chapter 9 in Pharmacy Practice for Technicians, Delmar Publishers, Inc., Albany, New York, 1993.

Kelly WN. Being a Good Pharmacy Manager: The Art of Managing for Employee Success. Chapter 14 in the Handbook of Institutional Pharmacy Practice, 3rd edition, ASHP, Bethesda, 1992.

Kelly WN. The Functions of Control and Evaluation in the Pharmacy Planning Process. Chapter 7 in Planning for Pharmacy Services, ACCRUE (Level II), ASHP, Bethesda, 1989.

Kelly WN. Organizing Data to Prove Your Point. Second in a Series on Advanced Hospital Pharmacy Management Skills, Biomedical Information Corporation, New York (Sept.) 1987.

Kelly WN. Applications for Electronic Infusion Instruments. Chapter 9 in A Sourcebook for IV Therapy, IVAC Corporation, 1985.

Kelly WN. Pharmacy Involvement in Patient-Care Committees. Chapter 26 in The Practice of Pharmacy, First Edition, Harvey Whitney Books, Cincinnati, pp 314-325, 1981.

Kelly WN. Extemporaneous Compounding (Sterile and Non-Sterile). Chapter 17 in the Pharmacy Technician's Manual, Second Edition, C. V. Mosby Co., Saint Louis, pp 194-212, 1978.

#### Editorials/Letters to the Editor

Kelly WN. Should pharmacists prescribe? (Editorial). *S J Health-Sys Pharm.* 1998;3:1.

Kelly WN. Pharmaceutical care in action. *S J Health-Sys Pharm.* 1998;3:1.

Kelly WN. Lead, follow, or get out of the ay! (Editorial). *S J Health-Sys Pharm.* 1997;2:4.

Kelly WN. They won't let me do it! (Editorial). *S J Health-Sys Pharm.* 1997;2:3.

Kelly WN. What do we expect from pharmacy computer programs?" An Editorial Response in *S.S J Health-Sys Pharm.* 1997;2:3.

Kelly WN. Is pharmacy really number one? (Editorial). *S J Health-Sys Pharm.* 1997;2:2.

Kelly WN. What would revolutionize the profession?" (Editorial). *S J Health-Sys Pharm.* 1997;2:1,5-6.

Kelly WN. Please tell me - I don't understand! (Editorial). *S J Health-Sys Pharm.* 1996;1:3 (Fall).

Kelly WN. Patient outcomes: Pharmacy must unstick itself now." (Editorial). *S J Health-Sys Pharm.* 1996;1:2.

Kelly WN. A new beginning for a new era. (Editorial). *S J Health-Sys Pharm.* 1996;1:1 (Spring).

Kelly WN. From adverse drug reactions to adverse medication events," (Editorial), *J Pharm Prac.* 1996;9:219.

Kelly WN. Medication misadventuring - A major health care problem?" (Editorial). *J Pharm Prac.* 1996;9:157 (June).

Chrymko M and Kelly WN. Are there really pharmacists in hospitals? (Editorial). *Am J Hosp Pharm.* 46:2000-2001.

Kelly WN. Comments on drug information centers: Lack of generic equivalence (Letter), *Drug Intell. Clin. Pharm.* 1989;12:301-302(May)1978.

Kelly WN. Omission in drug information centers: Lack of generic equivalence article (Letter). *Drug Intell Clin Pharm.* 1978;12:53.

Kelly WN. More on drug information as endangered species (Letter). *Am J Hosp Pharm.* 1975;32:1099.

Kelly WN. The foremost problems associated with formulary management. Guest Editorial in *Hosp Pharm.* 1983;18: 134-35.

Kelly WN. IV therapy team. (Letter). *Am J IV Therapy* (June-July), 1976.

Other Publications

Kelly, WN. Was it the drug? *MesScope Pharmacists*. <http://www.medscape.com/viewarticle/569794>. February 12/08.

Kelly WN. Concerns about study on Beers criteria. *Am J Health-Syst Pharm*. 2007;64:138.

Kelly WN. Medication Issues: Seven tips for Reviewing Cases. *LNC Resource*. 2005;2(4):11.

Smith LL, Kramer SV, and Kelly WK. Are pharmacists' and patients' expectations of each other the same? *Georgia Pharm J*. 2004;26(10):19-22.

Voiles KM and Kelly WN. Potential interactions between oral contraceptives and other medications and natural substances. *US Pharmacist*. 2004;29(1):61,64-66,68.

Steele DR and Kelly WN. Documenting errors benefits patients, pharmacists. *Drug Topics*. 2004;January 26;66, 71.

Housley S, and Kelly WN. Drug interaction monitoring – the good, the bad, and the ugly. *Drug Topics*. 2003;September 1;41-42.

Naik RM and Kelly, WN. The identification and documentation of significant patient risk problems in Florida pharmacies. *Florida Pharmacy Today*. 2002;67:19-22,26.

Burns S, and Kelly WN. Ten drug interactions every pharmacist should know. *Pharm Times*. 2002;November:46-48.

Marcellino K and Kelly WN. What do Georgia's patients expect from their pharmacist? *Georgia Pharmacy Journal*. 2001;23(10):22-23.

Kelly WN. Basic bibliographies: Drug-related morbidity and mortality. *Hosp Pharm*. 2001;36:453-55.

Kelly WN. Basic bibliographies: Significant drug morbidity and mortality. *Hosp Pharm*. 1994;29:723.

Kelly WN. Healthcare in the year 2000. *Profiles in Hospital Pharmacy*. 1990;March:2-3.

Kelly WN. Target Drug Monitoring: An advancement in drug use review and clinical practice. *Hosp Pharm Hotline*. 1987; 1(4):2-3.

Kelly WN. Drug level monitoring: Can it survive our changing healthcare system? *The PfiPharmecs Management Letter*. 1987;March:1-12.

Kelly WN. Hamot Medical Center: Where drug review gains its own momentum. *The Audit Action Letter* 1978;4:1-8.

Kelly WN. IV teams need your help. *Hosp Pharm Response Cards*. 1976;4:1.

Kelly WN. Forged prescriptions: Toward solving the problem. *Stethoscope*. 1974;57:24-25.

**ABSTRACTS WITH POSTER PRESENTATIONS:**

“From Blackboard and Chalk to WebCT and CD ROM: Revision of a Biostatistics Program.” Grapes ZT, Jann M, Jackson RA, Kelly WN, et al. The Annual Meeting of the American Association of Colleges of Pharmacy. Salt Lake City, Utah. July, 2004.

“Antibody Response to Impurities in Human Vaccines.” Kelly, WN, Hogenesch, H, and Chen, B. The Mercer University Health Sciences Research Conference. Macon, GA. March 4, 2004.

“The Quality of Published Adverse Drug Event Reports.” Kelly, WN. The 19<sup>th</sup> International Conference on Pharmacoepidemiology. Philadelphia, Pennsylvania. August 22, 2003.

“The Evaluation of a Problem-Based Learning Innovation in a Drug Misadventures Course.” Kelly, WN. The Annual Meeting of the American Association of Colleges of Pharmacy. Minneapolis, Minnesota. July 22, 2003.

“An Analysis of Fatal, Permanent Disabling, and Life-Threatening Drug Events.” Kelly, WN. The 18<sup>th</sup> International Conference on Pharmacoepidemiology. Edinburgh, Scotland. August 21, 2002.

“The Completeness of Published Case Reports of Significant Adverse Drug Events.” Kelly, WN. The American College of Clinical Pharmacy Annual Meeting. Tampa, Florida. October 21-24, 2001.

“The Introduction of PBL in the First Semester of Pharmacy School.” Kelly, WN, and Hawkins, DW. The American Association of Colleges of Pharmacy Annual Meeting, Toronto, Canada. July 9, 2001.

“An Analysis of Over 800 Drug-Induced Life-Threats.” Kelly, WN, and Marcellino, K. The 16<sup>th</sup> International Conference on Pharmacoepidemiology. Barcelona, Spain. August 23, 2000.

“Chronic obstructive pulmonary disease (COPD) healthcare costs for veterans at the Atlanta VA medical center.” Cordi, FM, Bower, DJ, McDermott, TL, Mencke, NM, Stephenson, JL, Cannella, KAS, Kelly, WN, and Aguayo, SM. 2000 HSR&D, Systematizing Quality in Healthcare: Approaches That Work. 2000;193-194.

“Cost of Healthcare for COPD Patients at the Atlanta VAMC,” Cordi, FM, Bower, DJ, McDermott, TL, Mencke, NM, Stephenson, J, Cannella, KAS, Kelly, WN, and Aguayo, SM. *Am J Resp & Crit Care Med.* 2000;3:161. Presented at The American Thoracic Society (Am. Lung Assoc.), Meeting, Toronto, Ontario, May, 2000.

“Risk Factors for the Most Serious Vaccine Adverse Events Reports (VAERS),” Kelly, Mootrey, G, Garguiullo, PM, Strine, TW, Chen, RT, and the VAERS Working Group.” The Mercer University Health Sciences Research Conference, Macon, GA, April 27, 2000.

“Risk Factors for the Most Serious VAERS Reports.” Kelly, WN, Mootrey, G, Garguiullo, PM, Strine, TW, Chen, RT, and the VAERS Working Group. The 15<sup>th</sup> International Conference on Pharmacoepidemiology, Boston, MA; August 27, 1999.

“A Descriptive Analysis of 227 Case Reports of Drug-Induced Permanent Disability.” Kelly, WN. The 14th International Conference on Pharmacoepidemiology; Berlin, Germany; August 17, 1998.

“Fatal vs. Non-Fatal ADR’s Reported to the FDA (USA),” Kelly, WN. The 13th International Conference on Pharmacoepidemiology; August 25, 1997. Orlando, FL.

“One School’s Assessment of Its Graduates in Residency Programs.” Kelly, WN., AACP Annual Meeting. Indianapolis, IN; July, 1997.

“A Descriptive Analysis of 447 Fatal Medication Case Reports.” Kelly WN. The 12th International Conference on Pharmacoepidemiology; August 28, 1996. Amsterdam, The Netherlands.

“Missing Data in Case Reports of Fatal Adverse Drug Events.” Kelly WN. The 12th International Conference on Pharmacoepidemiology; Amsterdam, The Netherlands; August 28, 1996.

“Pilot Pharmaceutical Care Model in a Community Hospital Setting.” Larson RA, Hixson-Wallace, JA, Cornell DJ, Kelly WN, and Underwood JL. ASHP Midyear Clinical Meeting; December, 1994.

“A Shadowing Program for Entry-Level Pharm.D. Students.” Kelly WN, Jackson R, Nykamp D, Miyahara R. AACP Annual Meeting. San Diego, CA. July, 1993.

“Interest, Commitment, and Financial Resources for Nontraditional Pharm.D.” Programs in Pennsylvania. Kelly, WN. AACP Annual Meeting. Philadelphia, Pa., July 15, 1992.

“Marketing a Clinical Program.” Kelly WN. ASHP Annual Meeting. June, 1991.

“Developing a Theoretical Base, Vision and Practice Plan for Providing Progressive Pharmaceutical Care.” Kelly WN. ASHP Annual Meeting. June, 1990.

“Clinical Services Management Defined.” Kelly WN. ASHP Annual Meeting. June, 1989.

#### **GRANTS/CONTRACTS:**

Primary Investigator      Potential Vaccine Impurities and Possible Immune Disease. Vaccine Program Office. The U.S.

Department of Health and Humans Services. Submitted December, 2004 for \$118,500.

Applicant	My First Experience with Problem-Based Learning. Center for Problem-Based Learning, Samford University, Birmingham, AL. \$750. January, 2002.
Primary Investigator	Impurities in Vaccines and Immune Disease. Centers for Disease Control and Prevention, Atlanta, Georgia. \$70,000, 2001-2002.
Primary Investigator	A Meta-Analysis of Drug-induced Deaths, Permanent Disabilities, and Life-threats to Determine Common Risks. The Institute for Advanced Studies in Medicine. \$10,000, 1999.
Primary Investigator	Clinical, Economic, and Humanistic Outcomes of Clinical Guidelines Pharmaceutical Care on Veterans with COPD. \$480,488. Partially funded in 1997 by Glaxo Research Institute for \$100,000.
Co-Contractor.	The Provision of Drug Information at the 1996 Centennial Olympic Games. Funded by Pfizer and Solvay Pharmaceutical Companies for \$25,000.
Primary Investigator.	The Identification of Variables Associated with Disability from Prescribed Medication, August 15, 1996. Funded by the Institute for Advanced Studies in Medicine for \$10,000.
Primary Investigator.	The Identification of Variables Associated with a Fatal Outcome From Prescribed Medication, March 1, 1995. Mercer University Research Office for \$2,000.
Co-Investigator.	Process Criteria Used by Preceptors to Select Pharmacy Practice Residents, February 15, 1995. Funded by Glaxo Pharmaceuticals for \$10,000.
Co-Investigator.	The Development of a Therapeutic Care Map and Patient Compliance Information for Anti-Convulsant Medication, March 1, 1994. Parke Davis. Funded for \$100,000.
Primary Investigator.	Reducing Significant Drug Related Morbidity and Mortality. Funded in 1993 by Upjohn for \$5,000.
Co-Author.	Development of Curricular Resources to Expose First Year Students to the Clinical Practice Environment. GAPS grant submitted in 1992 for \$25,080. Approved but not funded.
Primary Investigator.	Hospital Pharmacy Research Grant Recipient. Project titled: "Reducing Post-Infusion Phlebitis Associated with the Use of Sodium Cephalothin." Funded by Roche Laboratories in 1973 for \$500.

#### **CURRENT RESEARCH:**

The characteristics of the "good pharmacist."

#### **PROFESSIONAL PRESENTATIONS:**

International - Soviet Union (6), Republic of China (2), Canada (1), Netherlands (2), Germany (1), Scotland (1), and Spain (1)

National – Eighteen (18), including platform and poster presentations

Regional - Thirteen (13) where attendees were from several states

State – Sixty (60) in 35 different states.

#### 1992-1993

Lectures (6) and Workshops (3) on "Implementing Pharmaceutical Care", American Society of Hospital Pharmacists, Indianapolis, Indiana, November 4-7, 1992.

"Implementing Pharmaceutical Care," Atlanta Area Director of Pharmacy Breakfast, sponsored by the Mercer University School of Pharmacy, Department of Pharmacy Practice, December 1, 1992.

Workshop on "Implementing Pharmaceutical Care," Georgia Society of Hospital Pharmacists, Atlanta, Georgia, January 9, 1993.

"The Cost Impact of Biotechnology Drugs," Georgia Society of Hospital Pharmacists and Georgia Hospital Association Meeting, Atlanta, Georgia, January 13, 1993.

"What is Pharmaceutical Care?" Georgia Society of Hospital Pharmacists Meeting, Atlanta, Georgia, February 27, 1993.

"What is Pharmaceutical Care?" Mercer University School of Pharmacy, Telnet Presentation, Atlanta, Georgia, April 7, 1993.

Lecture and Workshops on "Pharmaceutical Care," Mercer University School of Pharmacy Alumni Day, Atlanta, Georgia, April 24, 1993.

"An Update on the American Society of Hospital Pharmacists Conference on Implementing Pharmaceutical Care," Florida Society of Hospital Pharmacists Meeting, Orlando, Florida, August 20, 1993.

#### 1993-1994

"Making the Transition to Pharmaceutical Care," Georgia Society of Hospital Pharmacists Regional Meeting, Macon, Georgia, September 9, 1993.

Lectures and Workshops on "Implementing Pharmaceutical Care," VHA North Central, Directors of Pharmacy, Millie Locs, Minnesota, September 15-16, 1993.

"The Business of Hospital Pharmacy," Pennsylvania Society of Hospital Pharmacists Annual Meeting, Lancaster, Pennsylvania, October 13, 1993.

"An Update on the American Society of Hospital Pharmacists Conference on Implementing Pharmaceutical Care," Georgia Society of Hospital Pharmacists Annual Meeting, Athens, Georgia, October 17, 1993.

"Pharmaceutical Care: Fantasy or Reality?" SE Regional Meeting, Kappa Psi Fraternity, Atlanta, Georgia, January 8, 1994.

Lectures on "General Principles of Pharmacology", "Introduction to Pharmacokinetics", "Investigation Drugs and Writing Prescriptions." Georgia State University, School of Nursing, Advanced Pharmacology, Nurse Practitioner Program (MS), Atlanta, Georgia, (January), 1994.

Lectures (2) and Workshops (2) on Implementing Pharmaceutical Care, Rockdale Hospital, Atlanta, Georgia, January 13 and 20, 1994.

"Pharmaceutical Care and Clinical Problem Solving," Mid-Winter Pharmacy Seminar, Bismarck, North Dakota, February 5, 1994.

"Pharmaceutical Care: Assuming Responsibility for Drug Therapy Outcomes," Mid-Winter Pharmacy Seminar, Bismarck, North Dakota, February 6, 1994.

Workshops on the ASHP Conference on Implementing Pharmaceutical Care, Tennessee Society of Hospital Pharmacists, Nashville, Tennessee, Mercer University (Atlanta), March 5, 1994.

"Pharmaceutical Care: Reality or Dream?" Continuing Education Conference on Managing Patient Therapy Through Pharmaceutical Care, Mercer University (Atlanta), March 6, 1994.

"Managing for Pharmaceutical Care," Continuing Education Conference on Managing Patient Therapy Through Pharmaceutical Care, March 6, 1994.

"Pharmacy Automation," Computer Users Group (HBO), Atlanta, Georgia, May 10, 1994.

Workshop on Pharmaceutical Care, Georgia Society of Hospital Pharmacists Regional Meeting, Atlanta, Georgia, May 21, 1994.

Workshop on Pharmaceutical Care, Georgia Society of Hospital Pharmacists Regional Meeting, Thomasville, Georgia, June 18, 1994.

Lectures on "General Principles of Pharmacology", "Introduction to Pharmacokinetics", "Investigational Drugs" and "Writing Prescriptions." Georgia State University, School of Nursing, Advanced Pharmacology, Nurse Practitioner Program (MS), Atlanta, Georgia, (June) 1994.

#### 1994-95

"Pharmacy Contributions to Negative Medication Events." Invitational Conference on Understanding and Preventing Drug Misadventures. Sponsored by the ASHP Foundation, in cooperation with the AMA and ANA, Washington, D.C., October 21-23, 1994.

Lectures on "General Principles of Pharmacology", "Introduction to Pharmacokinetics", "Investigation Drugs and Writing Prescriptions." Georgia State University, School of Nursing, Advanced Pharmacology, Nurse Practitioner Program (MS), Atlanta, Georgia, (January), 1995.

"Pharmaceutical Care and the Diagnostic Imaging Patient," American Pharmaceutical Association Meeting, Orlando, FL, March 26, 1995.

Lectures on "General Principles of Pharmacology", "Introduction to Pharmacokinetics", "Investigation Drugs and Writing Prescriptions." Georgia State University, School of Nursing, Advanced Pharmacology, Nurse Practitioner Program (MS), Atlanta, Georgia, (June), 1995.

#### 1995-96

"Impacting Patient Care Outcomes." Leadership Seminar. Southeastern College of Pharmacy, Miami Beach, FL. November 11, 1995.

"Drug Misadventures." Leadership Seminar. Southeastern College of Pharmacy, Miami Beach, FL. November 11, 1995.

Lectures on "General Principles of Pharmacology", "Introduction to Pharmacokinetics", "Investigation Drugs and Writing Prescriptions." Georgia State University, School of Nursing, Advanced Pharmacology, Nurse Practitioner Program (MS), Atlanta, Georgia, (January), 1996.

#### 1996-97

"The Mercer University School of Pharmacy Curriculum." School of Pharmacy University of Montreal. Montreal, Quebec, Canada. June 20, 1997.

"Pharmacists' Contributions to Adverse Medication Events," Twenty-Fifth Annual Pharmacy and Law Management Conference, University of Florida, Daytona Beach, Florida. October 26, 1996.

#### 1997-98

"Lectures and Cases in Pharmaceutical Care," the UGA/Mercer Non-Traditional Pharm.D. Program, April and June 1998.

#### 1998-99

"Lectures and Cases in Pharmaceutical Care, the UGA/Mercer Non-Traditional Pharm.D. Program, February and May, 1999.

Panel member at the "Symposium on Drug Safety," Georgetown University's Center for Drug Development Science, June 9, 1999.

#### 1999-2000

"Developing New Strategies to Solve an Old Problem – Medication Errors," to the Pharmacy and Therapeutics Committee and Members of the Medical Staff, Redmond Medical Center, Rome, GA., April 11, 2000.

"Experience with Implementing a Web-based Pharmacy and Law Course," to the faculty at Mercer School of Pharmacy, Mercer University, Atlanta, GA, May 3, 2000.

#### 2000-2001

"The Risks and Prevention of Significant Adverse Drug Events." To the faculty of the School of Pharmacy, the University of Washington, Seattle, WA, December 5, 2000.

“Vaccine impurities and immune disease.” Center for Biologic Evaluation and Research, FDA, Bethesda, MR. March 12, 2000.

“The Potential Risks and Prevention of Significant Adverse Drug Events: An Analysis of 20 Years of Case Reports.” To the professional staff on ASHP. Bethesda, MR. March 13, 2001.

“Risk Factors in Very Serious VAERS Reports. Presented to the Vaccine Safety and Development Group of the CDC. June 17, 2001.

#### 2001-2002

“ADE Knowledge Review.” Conference on Safe Medication Practice. NOVA Southeastern University, Ft. Lauderdale, Florida. November 10, 2001.

“Fatal Medication Errors: What We Know.” Conference on Safe Medication Practices. NOVA Southeastern University, Ft. Lauderdale, Florida. November 11, 2001.

“Assessing System Causes in Medication Erroring.” 12th Annual Program on Contemporary Pharmacy Issues. NOVA, Southeastern University, Ft. Lauderdale, Florida. May 5, 2002.

“Drug Errors Causing Death.” 12th Annual Program on Contemporary Pharmacy Issues. NOVA Southeastern University, Ft. Lauderdale, Florida. May 5, 2002.

“Ten Drug Interactions Every Pharmacist Should Know.” ACS Annual Meeting on Bridging Client Needs with PBM Services. Savannah, Georgia. May 6, 2002.

“Ten Drug Interactions Every Pharmacist Should Know.” Pharmacy Alumni Day. Mercer University, Atlanta, Georgia. June 22, 2002

#### 2002-2003

“Risk Factors for the Most Serious versus the Least Serious Vaccine Adverse Event Reports (VAERS). Presented to the Vaccine Safety and Development Group, National Immunization Program, Centers for Disease Control and Prevention, Atlanta, GA. July 1, 2002.

“Improving Medication Safety.” An Audio Conference to Hospitals on JCAHO’s Proposed Medication-Use Standards: How to Improve Methods and Achieve Compliance. Provided by HcPro. July 18, 2002.

“The Power of Reflective Thinking to Making Learning Better. Teaching and Learning Seminar.” Mercer University School of Pharmacy. February 5, 2003.

“Medication Errors: Lessons Learned and Actions Needed.” The Annual Meeting of the American Society of Safety Engineers. Atlanta, Georgia. March 14, 2003.

#### 2003

“The evaluation of a problem-based learning innovation in a drug misadventures course.” Presented at the Annual Meeting of the American Association of Colleges of Pharmacy Meeting. Minneapolis, MN. July 22, 2003.

“Vaccines and Potential Immune Disease: An Update of Research.” National Immunization Program, Centers for Disease Control and Prevention. Atlanta, GA. October 28, 2003.

#### 2004

“Improving Medication Adherence and Health Outcomes.” Case Managers. Excellus of Upstate New York. Rochester, NY. October 27, 2004.

“The Contribution of Pharmacoepidemiology to the Study of Drugs.” Department of Pharmacology. Medical School. Rush University. Chicago, IL. November 17, 2004.

“Improving Influenza Outcomes.” Managed Care of Greater New York. New York City. December 1, 2004.

“The 2004-2005 Flu Vaccine Shortage: Lessons Learned for the Nation.” ASHP Mid-Year Clinical Meeting. Orlando, FL. December 6, 2004.

“Insights to Influenza Outcomes.” Case Management Society of New England. Manchester, NH. December 13, 2004.

#### 2005

“The Contribution of Pharmacoepidemiology to the Study of Drugs.” Academic Seminar. School of Pharmacy. Mercer University. January 6, 2005.

“Improving Medication Safety: What Works? (Capturing Brer Rabbit in the Medication Safety Arena).” The Annual Meeting of McKesson Medication Management. St. Paul, Minnesota. June 28, 2005.

“The Types, Causes, and Reduction of Error in Pharmacy.” Continuing Education Program. University of Florida College of Pharmacy. September 10, 2005. Orlando, FL.

“The Types, Causes, and Reduction of Error in Pharmacy.” Continuing Education Program. University of Florida College of Pharmacy. September 24, 2005. Tampa, FL.

#### 2007

“Keeping Out of Trouble with Drug Interactions and Medication Errors.” Annual Meeting of the Georgia Pharmacist Association.” June 23, 2007. Myrtle Beach, SC.

“Guidelines for Submitting Adverse Event Reports for Publications.” Annual Meeting of the International Society of Pharmacoepidemiology. Quebec City, Canada. August 22, 2007

“Guidelines for Submitting Adverse Event Reports for Publications.” Annual Meeting of the International Society for Pharmacovigilance. Bournemouth, Dorset, UK. October 23, 2007.

“The Contribution of Pharmacoepidemiology to the Study of Drugs.” Tap Pharmaceuticals. November 12, 2007. Forest Park, IL.

“Pharmacoepidemiology and Its Role in Post-Marketing Surveillance.” The Chicago chapters of the Academy of Pharmaceutical Physicians and Investigators (APPI) and the Association of Clinical Research Professionals (ACRP). November 12, 2007. Forest Park, IL.

#### **COMMUNITY ACTIVITIES/SERVICE:**

Board Member - Tourette's Syndrome Association of Georgia (1994-1995)

Board Member - Community Blood Bank of Erie County (1992)

Member - Koinonia of Erie County (1989-92)

Secretary - Greater Erie Area Habitat for Humanity (1989-90)

Board Member - Mercy Center on Aging, Erie, PA (1989-92)

#### **PERSONAL DATA:**

Place of Birth: Bay City, Michigan

Family: Married, two daughters, son-in-law, three grandsons.

Licensure: Florida, Georgia, and Michigan